| Name | Title | Contact Details |
|---|
Welch Allyn Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Skaneateles Falls, NY. To find more information about Welch Allyn Inc., please visit www.welchallyn.com
At Smart Choice MRI, we put your comfort and convenience first. That doesn`t just mean giving you a scan using advanced GE technology and the expert interpretation by a Cleveland Clinic radiologist, for a fraction of what it would cost at a hospital. That means working with your schedule, offering early morning, evening, and weekend appointments, and doing whatever we can to make your scan a relaxing, comfortable experience.
MedAmerica is one of the leading healthcare practice management organizations in the United States. Since 1975, we have successfully managed hospital-based physician group practices across the Acute Care Continuum, with expertise in emergency medicine, hospital medicine, ambulatory & urgent care, and other acute care specialties. We provide the strategy, solutions, and systems to help our clients successfully navigate today’s complex healthcare landscape. MedAmerica offers a full range of cost-effective practice management solutions. We’re in the business of enabling physician groups, hospitals, and other healthcare organizations to be more efficient, productive, and profitable – all while providing higher quality care and improved outcomes.
Palo Duro Nursing Home is a Claude, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.